| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | Enterprise Standard |
| Suitable for: | Elderly, Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier Name:Fevipiprant
Specification:99%
Apperance:Almost white crystal or crystalline powder
Storage: Keep in a dry and cool place
Vacuum sealed foil packaging(1kg/bag),Export grade fiber drum (25kg/drum).
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Fevipiprant is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}